Basic Information

Gene symbol APOC3 Synonyms APOCIII, Apo-C3, ApoC-3 Type of gene protein-coding
Description apolipoprotein C3

GTO ID GTC1645
Trial ID NCT02910635
Disease Cardiovascular Abnormalities
Altered gene APOC3
Therapeutic/Target gene Target gene
TherapyASO
Treatment volanesorsen|ISIS 304801|ApoC-III|Approach|IONIS-APOCIIIRx|Waylivra|ISIS-APOCIIIRX
Location approved EU, UK, Brazil, Canada
PhasePhase1
Recruitment statusCompleted
TitleA Randomized, Placebo-Controlled, Four-Period Crossover, Study to Evaluate the Effect of Volanesorsen on the QTc Interval Using a Therapeutic and Supra-Therapeutic Dose Compared With Placebo in Healthy Volunteers: a Thorough QT Study
Year2022
CountryBelgium|Brazil|Canada|Germany|Netherlands|Russian Federation|United States
Company sponsorIonis Pharmaceuticals, Inc.
Other ID(s)ISIS 304801-CS13
Vector information
VectorNo vector was used

Clinical Result

Cohort1: Volanesorsen_Intravenous infusion
Administration route intravenous infusion
Dosage Volanesorsen, 300 mg, single dose
Age Adult
Cohort2: Volanesorsen_Subcutaneous Injection
Administration route subcutaneous injection
Dosage Volanesorsen, 300 mg, single dose
Age Adult
Cohort3: Moxifloxacin
Administration route oral
Dosage Moxifloxacin Hydrochloride, 400 mg, Single Dose
Age Adult
Cohort4: Placebo_Intravenous infusion
Administration route intravenous infusion
Dosage Placebo, single dose
Age Adult
Cohort5: Placebo_Subcutaneous Injection
Administration route subcutaneous injection
Dosage Placebo, single dose
Age Adult

Relationship Graph

Overview of Knowledge Graph